PDA

View Full Version : Super-DMZ rx~Dimethazine (updated 2011)



heavyiron
12-24-2010, 05:05 PM
Super-DMZ rx by heavyiron

Super-DMZ rx, is an over the counter legal product that contains 10mg of Superdrol and 10mg of Dimethazine per capsule. Dimethazine is two steroid molecules bound together by a nitrogen atom. Upon ingestion, stomach acid separates the two steroid molecules that closely resemble methyldrostanolone (Superdrol) Therefore Super DMZ contains both Superdrol and Dimethazine. Dimethazine once broken down is similar to Superdrol though.

Dimethazine was a prescribed steroid at one time therefore we have human trials in which this steroid was used. This medication has been around since 1962 when it was presented in the literature. Early on it was sold under the Roxilon brand name. Dimethazine is basically an oral Masterone (drostanolone propionate). Published reports indicate that Dimethazine possesses an androgenic rating of 96 and an anabolic rating of 210. Furthermore it seems to possess little to no estrogenic or progestational activity. The reason I feel this is not identical to Superdrol is because Superdrol has a different androgenic/anabolic rating of 20/400 respectively. However Dimethazine is a strong steroid on its own. The addition of Superdrol makes Super DMZ rx an even stronger steroid.

Dimethazine is an oral c-17alpha alkylated steroid that is liver toxic to a degree. Note that in studies administering 20mg daily to female patients for 45-95 days, dimethazine was shown to induce modest to moderate bilirubinemia (excess bilirubin in the blood, indicative of hepatic stress) in close to 50% of patients. Approximately 25% of the patients noticed substantial increases in serum transaminases. These results suggest this steroid has significant hepatoxicity and should therefore be limited to shorter durations of use. Superdrol is also known for hepatoxicity so care must be taken when using Super DMZ rx.

Super DMZ is a potent oral steroid that should illicit solid gains in lean body mass with little water or fat gain depending on diet. Most users can tolerate between 20-40 mg (1-2 capsules) daily for 4-6 weeks however more adventuresome users may use up to 60mg (3 capsules) daily for shorter durations like 2-3 weeks. What struck me the most about this steroid is how rapid and dry my gains were. It reminded me of a faster acting, dryer Dianabol. However Super DMZ rx is much stronger mg for mg than Dianabol. Users of Super-DMZ can expect to add 8-12lbs of lean body mass in just 3-4 weeks. I personally had no noticable side effects from Super-DMZ at 2 capsules daily for 4 weeks. Super DMZ rx is a strong, clean steroid that can be used to increase lean mass, strength and power with little to no water retention in short periods of time.

Lipid and Organ Support

Because of the liver toxicity of Super DMZ rx I strongly recommend using liver supporting supplements such as ADVANCED CYCLE SUPPORT™ - Complete 'On Cycle' Prohormone Support (http://www.ironmaglabs.com/advanced-cycle-support.php) and/or Liv 52 before and during administration of this designer steroid. Proper hydration is also recommended to lower stress on organs. Alcohol and other liver stressing medications like acetaminophen should be avoided during Super DMZ administration. Oral steroids often times negatively affect lipids therefore lipid supporting supplements should also be employed such as omega 3 fish oils, fiber and plant sterols. High blood pressure is another concern so that should be monitored regularly. Consult your health care professional before using any dietary supplements.

Post Cycle Therapy

Since Super DMZ rx will cause interruption of the Hypothalamic-Pituitary-Testicular Axis, post cycle therapy is strongly recommended. Bulbine natalensis or ProLensis™ is a amazing over the counter testosterone recovery supplement. It stimulates the production of GNRH and also increases cholesterol in the testes. Prolensis causes production of LH, which in turn signals the testis to produce testosterone. Evidence shows that ProLensis™ can stimulate LH 169% compared to study controls. Research further shows Testosterone is boosted a whopping 347%! This natural compound is a main ingredient in IronMagLabs Bodybuilding Supplements & Prohormones: Ultra Male Rx (http://www.ironmaglabs.com/product-list/ultra-male-rx/). Ultra male Rx also has pro sexual effects as well as boosting Testosterone. Some Testosterone boosting compounds may increase Estrogen but in rodent studies it was confirmed the the main ingredient in Ultra Male Rx actually decreases Estrogen by 35%. Ultra Male Rx is a legal way to significantly boost testosterone, control Estrogen and raise libido.

Sample Cycle

Weeks 1-4 Super DMZ RX-2 capsules per day
Weeks 1-8 Advanced Cycle Support-2 capsules per day (organ and lipid support)
Weeks 5-8 Ultra Male RX-1 capsule per day (post Cycle Therapy)

Super-DMZ rx is currently available for purchase without a prescription. Super-DMZ Rx™ Pro-Anabolic (Superdrol Dymethazine) (http://www.ironmaglabs.com/superdrol-dmz.php)

Chemical Name(s): Dimethazine
17beta-hydroxy 2alpha,17alpha-dimethyl 5alpha-androstan 3-one azine

http://www.ironmagazineforums.com/attachments/anabolic-steroid-profiles/34323d1313251122-super-dmz-rx-dimethazine-updated-2011-dimethazine.gif
Chemical Name(s): Superdrol
2a,17a-dimethyl-5a-androst-3-one-17b-ol
2a,17a-dimethyl-etiocholan-3-one-17b-ol
http://www.ironmagazineforums.com/data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAASYAAADeCAIAAAA fEDpNAAAgAElEQVR4nO3dSVMTW9ww8JbPkC8RWbBDVqy0ZEFZx YYqytJy4dUrC6tQq1QWlIiKIMgkMskQpgABQkJIyJyQARJCBjI yZCAhc8g8dbq76l308/DyeL2KkFxBz29hlRk6HSvtOX3Of4AgAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAA4JJDUTQWiyWTyV99IgDwZ/B4PL29vUwm81efCAD8GRwOR3V1dXV1tc1m+9XnAgC/L6vVSqPRvF4vBEEUCqW4uPjVq1eZTOZXnxcA/HYwDIMgSCAQXLt2raurK5vNcjic8vLy0tJSOp2OPwsAQB4gCOJ wOKRSqdlsjkQiL1++LC4ufvLkiUAg2NzcrKqqKi8v39zc/NWnCQC/hVwuJ5PJRkZGPn78ePv27cHBQafTeevWreLi4v39fQiC6HT6jR s3yGTyrz5TALg8vjMtVCqVjY2NYrHY6/W2t7cTicSxsTEul1tWVtbU1JTJZJLJpFardblc/+UJA8AlBsOwWCze2tr65rOTk5MNDQ0IgkAQFIvFHj16VFlZabF YXr9+XV5evr29/d+eLABcftFo9PHjx9XV1U6nE4KgXC53cHCws7ODb3OTSKS7d+/iT0EQJBQKq6urZTKZx+Oh0+n40iUAAD8Wj8dNJlMkEoEgiEKhE InE9+/fQxBkNBqfP39+/59DocDQZBGo6moqGhoaDg6OoJhWCgUNjY2Go3GX3z2AHDpOJ3O e/fu9fX1QRCkVCrLy8uLi4t5PJ5CoRgfH6+qqqqpqbFarRAEkcnk ysrKhoYGCoXS2dnJZrOz2eyvPn0AuCQSiYRAIJiZmZFIJM+fPy 8tLR0fH+dwOJOTk5WVldevX1epVBAEjY2N3bhxo76+/ujoCIIgDofz6tWrvr4+sVicSqV+9ZcAgEsiGo1++fLlxYsXz54 9Gx0dDQQC5eXlJSUlFosFgiAqlVpSUtLR0YEvlkxPT9+7d0+r1 ebxBDKZTC6Xy+MBAeDiQlGUTqc/ffrUZDJZrdbjSSOBQOjo6IAgKJFILCwsCASCdDq9t7fX09PT0d Hh8/lQFN3Z2ZFKpQKBYGlpyW63n+0EMpnM0tJSR0dHPB7P5xcDgIsp m83W1dXhVxfO5/P19/dfvXq1tLT0ZPgIhmFyuXxsbEyn00EQBMNwfX09kUgkEonXr19X q9VnOwEEQQYGBohE4uTkJP5IMBhks9mLi4tWqxWEjAG/GxiGHz58eOfOHRRF8UdWVlaqqqqGhoaGhoYkEsnJFycSiWg0il 8GCII8fvz4ypUrV65cqays9Hg8P/W5eDSmSCSCIMhms12/fr24uNjhcEAQRCaTa2trHz9+PDg4CG4Rgd8NhmFTU1NEInFwcB CCIBRFP3z4UFNTEwgEUBT9zi8ew7Cenp6ioqKioqK6ujoYhk/5iblcDg9Pefz4cUVFhV6vNxgMtbW1BALh5cuXmUxGoVAsLS29f Pnyzp07TCbT5/Pl56sCwAURDAYbGhquXbv29u3bgYGBuro6fPPth2g0GoFAKCoq 6uzsPOVnOZ3O2dnZZ8+e9fT00On0a9euVVRUkEgkrVaLB47hU9 xsNisWixsbG58/fz4/P3/27wYAF1MkEqHT6b29vf39/RqN5pRDFo/HIxAIBAKBzWaf5vXxePzjx48TExPT09NjY2PRaHRwcJBIJHZ3d 0MQ5PP5amtr6+rq8HUUFEU5HM6bN28WFxfP89UA4IJCUTQSiUS j0dO/Ra/XFxcXE4nEnZ2d07yex+PV1dUFg0EYhtPpNARBdrv99u3blZWV+ L6fz+dzOBz4bsTGxkZDQ8Pw8PDe3t6ZvhAA/OcwDEsmk6cs/qNSqf7666/6+noGg3HKXTKn03nt2rVr167929oJviSDnwYEQW1tbQ8ePEgkE vizkUikr6+vo6OjqqoKH+iOwTCs0WhEIpHdbsevQAC46FKplFQ qJZPJHA7HaDTGYrHvv35paQlfC/n7779Pecn5/f7KysqamprjsRHDMBiGEQTBBzGj0ajX651OJ5VKDYfDs7OzZWV lIpEIX/M0GAzl5eVyudxutxsMhq8OjqIo2CEALg2v10smk9+9e7eysrK1 tUWhUJaXlw8ODr5zk6ZWq/G1kObm5lN+SjQaffnyZVtbG4IgGIblcrl4PK5Wq61W6/r6utFoXF5eplAoZrP58+fPDocjGo1WVVVVVVUplUqz2Tw1NXX/n08hBoALqt0Or25udnW1tbT04OHkkAQFAwGuVzu4uKiSCQ6PDz 85oVntVpLSkqKiopev379w0/JZrN+v397e7u+vn5sbAyCoHA47PF4jo6O2Gz21taWTCZTqVQ6n U6pVB4dHalUqmAwCEGQWq2uqal58OBBfX39p0+f9Hp9Pr88APy XEARxuVwUCuXt27d0Ov2rW7hMJrO/v0+lUslkskKhwLfdTr7g8PCwoqLiypUr7e3t3/mUUCi0s7OjUChGRkZoNFpXV1dTU9Pe3l4ymUylUtls9vDwMBKJ xGKxdDqNL5PkcrmTU8RoNCoQCDgczsHBQX7/BQDgPxKPxy0Wi0ql6u/v/DhAx6O/E2RSESpVE5PT9PpdK1WGw6HTz71119/EQiEbxYsyWazPp9vf39/cXHx8+fPDAZDLBYHAoFEIjE+Pt7d3f2z0ScAcClhGOZ0OmdmZn p7e9lstlgsDoVCP3yXzWYTi8VTU1NMJvP4Bi+Xy3V1dRGJxJP7 4DAMJxKJvb09hUJBJpPJZDKNRpPJZCdrVO7v7zc3N1OpVFC4Ev jNJZNJuVze1dXV29trMBh+ajEdhuG9vb3FxUUWi6XRaAKBAARB q6urJSUlXC4XgqBcLnd4eCgSiZhM5vDwMJ1OX1tbOzg4+OenoC gqkUjGx8fZbDZYCwF+WwcHB7Ozs+/fv6dSqWdOewkGg3q9nslkrq6umkwmFotVXl5OpVJDodDa2tri4 mJ3dzeLxdre3v7+FjmGYRaLpa2tjUqlgm004HeTzWY3NjY+fvz Y2dl55pSZkzwej0QimZub+/LlS1lZWV9fH5fLnZqaUiqVRqPx9JtjeFSkRqM5/ykBwEWBYZhUKm1oaJidnfX7/fk6LAzD+/v7S0tLz549W1lZsdvt+FTzp2Sz2fHx8c7OTrxMAwD8DhKJBIlE mp2dLcT8LRwOK5XKM1xsx1wuV2tr68LCApheApcGDMNWq/Xf6hwfHR2xWKwCVUGOx+NSqfScfaqkUmljYyMepgwAl4DP5/v7779bWlrwv6ZSKafTGQgE8LjHUCjEZrMLtInscrlmZmbMZvN5 DpLNZicnJ/H6KPk6MQDIv3Q6jd+bxWKxurq6srIyhUIBQdDKysqLFy+6uroO Dw8hCAqHw0tLSyqV6qvYkbwIhUKrq6unzMT5Do/HQyaT5+bm8JYgAHARmUyme/fu4YEjy8vLBALhzp07BwcHCwsL79+/r6mpwUMZEQQRi8UKheL0hQ9OL5FIyOXyfwb1n0EkEpmYmOjs7D wuog4AF0I6ndbr9RKJRKFQlJaW3r17d2NjY3Jy8vHjx6WlpU+e PDk4OHA6nfX19Xfv3mWxWIlEQqFQbG9vF6LwYzQalUgkJpMpL0 dzOBzt7e1TU1Mnw8oA4FfCyx+8ffu2rq5OrVavrKwQicSqqiqb zRYIBJ49e0YkEmUyGQRBh4eH7e3tT5488Xg8JpPJYDAU4pKLxW Lr6+t5nA1yOJzGxsa8DJsAkAdzc3M9PT0CgUAikeCh/Y2NjUQiEV8z1Ov1r1+/lsvlEATZ7fbm5uZPnz5FIhGTyWSxWAqxCh+Lxfh8/r81uDqD9fX18fFx/C4UAH6xcDj85MkTHo93nNsSj8c5HM6NGzeqqqoSiQSGYbFYLJP JIAhCpVLb29utVmsulxOJROvr64XouZFKpUQikVQqzcvRdnd3y WSyXq8Hyd3AheBwOCorKykUCv6LxDBsYmKisbFxamrq4cOHJ3f eUBQ9PDw8zo5RqVQSiaQQYfswDOt0urxEbMEwvLS0ND8/D8qeAxcFDMP379+vqKjAVykRBHnx4kVTU1MikXC5XP82iCEIYj AYCnQvl81m5XI5XkH5nAwGA1764fyHAoC8EQgEFRUV1dXVNBpt bW3txYsXSqXy+29BEEQikQiFQryeT37lcjmj0Xj+tsNer5dKpe a3Ow8A5AFeOq6pqam+vn5oaEir1f5w7EIQRKfTbW9vF2JfDi9O ji/YnFk0Gp2bm2MwGKCdAHBBwTAcDoePqzt+XzablUgkGxsbhVg+g WFYJBJRKJTzhLYYjcaRkZHd3d08nhgA5E02m5VKpTQabXFx0Ww 2/3BxD0VRgUDAZDILMYagKLq3t6dUKs98o+hyuebm5vBuWABwEbn d7oqKiqKiIgKB0NfXd5r1dKvVqlAoClRoxGKxnHlfLpFILC0tL S4ugiIowMUVDAZLS0vxLm1tbW2nueRsNtv6+noh7uUODw+/fPkyPj4eiUScTucp57rHtre35+bmQAIB8H9Eo1GTyeRyuQrxkz 2bmpoavDL5hw8ffngT5ff7p6ampqamTCZTvra8UBSFYdhkMnV1 dXV1danV6p2dHQaDoVAo3G632+32+/0/XCA9OjpaWVkBU0rg/3A4HAMDAw8ePOjo6DhP7vMPuVwujUbj8Xji8fgPr6L6+nr8kqN QKN95GYqiZrN5cHCwr69PJBItLi4uLy/v7e2d8/+OQCCwtra2vr7++fPnyclJ/J8lHo87HI69vb3Nzc2NjY319XWhUKhWq/1+fzQa/We3AHzrgs1mF2LrAriUMAzb2dn5+PHjwMAAg8EQCoWn7Efzs7L ZrEKh6OzsHBwc5PP5PB5Po9F8/7O6uroIBAKRSPzOTVQ4HGYyme3t7QsLC16vN5fLeTweLpc7MjI iFArPFsSIoqjJZBocHOzq6pJIJGaz+Z+roIlE4ujoKBQKSSQSG o22sbEhlUoNBoPNZsN7DOAvczqdS0tLIDsO+P8SiURvb29zc/PxnX0mk3E6nfmtu+j1emdnZ9++fUulUl0ul8vlkkgks7OzPB7P 7Xb/2zIghUIhEAglJSXfjLjHB7fh4eGenh6FQnHyqoBh2GKxrKyszM 3Nra+ve73e059qOBzmcDjt7e0jIyOnLOMVDofdbrfVatXr9Wq1 msfjCYVCh8NxcHBApVI3NzdP/+nA7y8UCtXV1dXV1R0/olAonj17JhAI8L8iCHKezSgEQVQqVUdHR2dn58myH9ls1mKxMB iMlZUVuVz+zZpcfD4fH+W+Cm7MZrNut5vNZre2ts7MzLjd7m9+ dDwe1+v1+FKhXq8/zeqFxWIZGRlpbW1ls9mnqe78zQ91uVwWi0Wn00kkktXVVVAgHf g/YBju7u4uKSlhMpn4I8PDw9evX+fz+RAEJZNJo9GIT5N+dos5lU p5vd7FxcWmpqbZ2dlv/vLwjBsGgzEzM6NSqSKRyMnUm4ODg5KSkrKyspMJ1Ha7nUKhzM7 OLiwsrK2tnWb1QqfTiUSi5eVlqVT6zTvVXC4XDAZ5PN6HDx8GB wf1ev35M4AymUwoFPrZtU3gd5PJZLa2tr66tQgEAo8ePbpx4wa DwdDpdE+fPm1qasJ/mtvb2zQa7ejoSKPRbG5unv6HuLGxMTExQaPR+vv7pVLp9y9Xn8/H5/OXlpaoVKpQKHS73cc5BNevX6+pqcG7LqbT6Y2Njd7e3uHhYb1e/8NWjCclk8mdnR0ej4d/xMl6kl6vd2xsjEKhTExMrKysgKV8IJ98Pt+9e/f+/vtv/DedzWaNRqNQKOTxeK9evfrrr79evnw5MjJynCCztra2trYWCoU GBgYUCoXH4/lhVdajoyMKhdLQ0ICXxDplFVe8f41MJpubmyOTyWq1Gr9K79+/X1dXl8lk/H4/lUrt6upaXV3FG7KdQTKZNJlM8/PzFAoFH1QVCsX79++7u7t1Op3f7784GyTA5YbnleENzb58+VJS UjI7OwtBkEajefr06YMHD3p6emw2Gx7TdLIgh9frjcfjoVAIn5 LhrXS9Xq9MJvvmwGUwGDo6Otrb2+Vy+Rk2x3K5nN/vF4vF4+PjYrE4mUy+efOmrq5OqVSOjY2NjIxYLJbzh1BGo1GNR rO8vDw6Oop3xjnzNQwA3yaVSm/durW4uAhBkEAgIBKJFRUV+/v7DoeDyWS2tLSUl5fjdbK+CUGQXC6HD0SZTEar1SoUilQqFQ6H j6/PaDRKpVLfvn1LJpMdDsd58p1hGLbb7SKRSCaT3b59+/r16729vRwO52zrGd+EYVggEKBQKEwmE+yYAfkXCoUqKipu3rw5 Ojo6MTExPDxcXl5+7969UCiE57w8ffr07t27p0zBzGQyMAzncj mXy4Xf8gUCgb6+vubmZplMlq+oYnyvorm5+eXLlwaDIe9Tvmw2 KxQKVSoVqIYAFIRIJCISieXl5cFgMJPJDA0NFRcXT05O4s9qNJ pnz57Nzc391DGPa5MYjcaFhYX9/f28l23VarVyubwQid4wDG9sbGxuboL7N6AgMAzr6OggEokMBgP DML/fPzk5idfPOTg4+PTpU0tLy9mqER8dHQkEguOG9/m1ubkplUoLcVUgCKLVavOyHwAA33Z0dFRVVVVeXo5fHnhAIIZh drudx+Pp9fqz/bK9Xi+DwShQMQ+JRDI/P1+I3a1cLqdQKApUEQwA/odSqaytrbXb7Xk8psfjWVhYOH+9/m/S6XQ0Gq0QYZ8IgqjVarlcDnargcLK+883FAqJRKICVdg3m80sF uundr1PCcMwo9Go0+nAKAdcMoFA4Mwx+z9kMBhmZmbyuD1wDEX R7e3tAhXhA4ACwpdPCpSfsrOzw2KxCjSxVKlUarUaXHLAJXN0d CQWiws0sbRarQwGI4+9v49hGCaXy7lcLriXAy4Zn88nFAoLcVV AEOTxeGg0WoHaEWs0GqlUCqpKApeMx+Nhs9kFupeLxWIymaxA0 f0mk0mlUoFLDrhk8BXLAu3LBQIBDodToEtud3dXJBIVtNYLAOQ fvmJZoLlfPB7n8/kFup5NJlPhrmcAKBS/389kMvf29gpx8EQiwWazHQ5HIQ7udDplMlmB7kIBoFACgcDq6m qBNglisdjs7GyBQlv8fr9cLgetTIFLxu/383i8Av1wMQxTqVR4v+K88/l8XC4XVLwDLplgMMjhcAr3w1WpVAUqkmWxWCYnJ81mcyEODgCF kkgkNBpNgUY5tVr98eNHsVic96V8vV7/6dOn4zLMAHBpRCIRFouV9+WTRCLB5/PfvXs3OjrKYrHEYrFOp8tLcFY0Gl1ZWXn/v3Y2Ng5a0YAwH8tEonMzc319PQwmUy9Xp+vqHyr1frlyxe8urP f7w8EAniBIJFI9FUZ2Z9lsVgGBgba2tq4XO7JwkoAcAlsb2/39vYODQ2ZTCa8AiyLxTpnMl4mkxGLxa2trZ8+fdrc3DyeT+LNB tbX1ykUytluHQOBAF7gmUQi7e7ugmhm4NLAO2DQ6fSOjo7l5WW 8DGs0GnU6nRwOZ2Jigs1mn61Mnc1mI5FIb968mZ+fPzw8/OeUD69BxOFwJicn+Xz+KbfU7Hb74uLi4uLi4OAgk8kEgxtwmVi t1vn5+cnJyYmJCZ1OhyCI1+udmZkRCAQoiqZSKaPRSKVSJycnB QLBKZuG5nI5tVrNYDBGRkZ6e3vX19e/n62TTCbNZjOdTieRSHi5y++8mM/nNzc3r6ysOJ1Op9MJSugBF9T+/n5vb69SqTweapLJpEwm+/Lly9zc3O7ubiKRyGazm5ubXV1dfX19J8sNRaNRvV4/MzNDpVK1Wu33L7xoNDo1NdXQ0MBgMCwWi8/nO039HwzD4vG4TqfD+xN8M9M0FAqNjIx0dHSoVCrQMRi4oDAMQ xAEw7BEIlFTU1NdXY0nwsViscXFxb6+PolEkkqlEomEUqlcXFx sbW1dXl7+51QNw7BIJGK1WplMJoPB0Gg0mUzmq4liLpfTaDRtb W3t7e1arfYMSy/4p8jl8uXlZQ6Hc3h4iFf1y+VySqWyra2NQqGASszAhba/v/p0ycqlZpKpZRKZXl5eWtrayaTiUQiPB5vf38/l8vhVdC/fPnCYrG2tra+v8ieSqXMZjODwVheXjaZTDAM42XFQqEQ3rqAQq Gc8+YKQZBwOCyRSJaWljY2Nlwu18zMTHNzs0KhAIMbcNGJxWIi kUggEB4/fry1tdXQ0FBeXi4SifDR77gKOl5XPJVKnXJTK5lMKpXKhYUFNp ttsVjwwa2lpWVzczNf1WYzmYzZbOZyuWNjYyQSCUROApdDIpGo r6+/cuUKkUh8/fp1XV1dUVFRZWUlPr1cW1vr7e09c4RUOBwWiUTz8/P9/f0kEumnmpueUiwWc7vdoAAzcJns7++Xl5ffunVLoVDw+fyKigo CgcDlciEI8vl85wy8wgtFOxwOUMoOAP6/mZmZsrKy7u5uBEH29/epVGqBMtYAAIAgCEomkw8fPrx586Zer/V5wIAfwaj0bi0tASKFADAf8rr9YLwKAD4j4TD4YWFBaPRCNJbA OC/4HQ6SSSSwWD41ScCAH8Gm802PT1doFI/AAB8zWw2k8nk/DajAwDgX0UiEY/HA/r6AsB/BEEQhUJRoErJAAB8ze/319TUPHnypBAdFQEA+B/RaHR9fR1fNRkaGiotLZ2amgLTSwDIp0QicXBwoFAoXC6XWq0uL y8vKyubn593uVz37t27fv062CoAgPyIx+Mmk2lubq6/v390dHR/fz8SidTU1BAIhOrq6s7OzmvXrhUVFT158gSUWAX+RBiGpVKp82 e+ZLNZj8ejVqunpqYGBwdJJJJEIolGo3jKtkwmq6ioqK+vZ7FY tbW1eNIqg8HIy1cAgEsDz61ms9nr6+t+vz+TyfxsoQEMwwKBgN lsZrPZQ0NDfX19c3Nzdrs9lUqhKJpMJg0Gg1AojMfjfX195eXl YrEYgiA6nV5XV7exsVGYrwUAFxLeTr6zs3NhYUEkEm1ubsrlco VCcXR0dJqCCLlczuv1KhSK0dHR4eHh6elpmUzmcDhSqRQMwwcH B3w+f2FhYXBwkEwmRyKRZDJ569at43xwAPizZLNZlUpFoVDUan UikYAgKBgMSqVSiURiNpvX19f39vbi8fg364jE43GHw7G6ujo6 OjoxMUEmk61WK36leTwegUBAp9MnJibwWpRGo/G40iOPx2tsbASNaYA/TiAQWFxcfP/+vUKhOPk4giDpdNrv929sbKyvrwuFQofDEYlE/H7/cVFHDMO0Wu3k5GRXV5dUKvX7/XhJPK1WS6PR8CtQIBBsb2/8/4QQZBkMgm2B4A/y9HR0fT09MePH5VK5b/9+nO5XCQS0Wg0ZrNZqVSKRCKXy+VyudLpNAzDNpvNYDB4vd54P O50OhUKBZlMnp6eJpPJBoPh+6WOAeDSQBDknOXiUBS12+1kMnl 2dtbtdp/mLdls1mazWSwWl8vFYrFMJpPX6zWZTA6Hw2QyjY6OUiiUkZERo VDodrtB7inwm0AQZGdnR6/XW61Wj8dztg4vuVxOLpe3trb29vaeofgchmF2u/3g4GB/f59GozU3N/f19S0vL+/v74MCj8DvxmKxtLa28vl8lUrFZDLtdrvNZvN6vT+1oK9Wq9vb2/Geg+c5mXQ6bbFYhoeHtVotSO4GfkO7u7skEmlxcTEUCsViMYvF YrPZ6HS6QqEwGAw6nS4Wi+FF/tCOl0WiaTDQ8P4/tj5z+lVColFovxllQA8PvAexG2tLRQKJSTq3+5XM5isXg8np2d ncXFRa1Wq9PpHA7H0dHRP8e9QCAwMzPT0tLCZrPz1XMwl8utrq 5ubW3lqxQ5AFwIbDa7qamJRqNFIpFvviCXy7ndbqfTKZFINBqN Wq1eXV3FN6PxSxTDMCaT2dXVJZfL89uNXqlUSiQSUDYc+E2kUq mtra2RkZGtra3TDE2RSCQcDvt8Ph6PJxAIRCKRXC7f2dnh8/lUKvWUi5M/xWq1slisf/u/AAAuk4ODg4mJiba2Np1O97PvTafTHo9na2tLLBbj/ZkKFOrh9XpXVlZAKgBw6R0dHQ0NDX38+FEikZw5uj+Xy0WjUbF YPDY2VqC9slQqxWQyPR5PIQ4OAP+Rg4ODubk5KpVqt9vPvzKxv 7+/urpaoHVFFEVpNBrYJwAuq2w2iy9OkkikfM3WbDYbg8EoXG0fHo 9Hp9PztQoKAP+pzc3NlpaWubm5PEZyuN1uCoXyVeByHu3u7s7P z+dlow8A/lNbW1vj4+NbW1t4Ek2+pNNpoVDI5/PzeMyT8BUUEFcJXDJarbaxsVEkEuU9pQXDML1ev7q6WqCBKBqN Dg0NgeQ34JKRSCRTU1OFGCswDNvd3eVwOMFgMO8HhyAIhmEej6 dSqc5/KBRFs9ks6DwM/BfMZjOXyy3QnrLVaqXRaAXqAYBhmEajodPp5x+f3W73s2fPmEz myYODhRmgIHZ3d1dWVgpUvdjr9S4vLxeuYuTu7u7Y2JjL5Trb2 1EUxUPGfD5fRUVFTU0NfqhcLre5uUkikc4QDAAAP+BwOKhUaoG W8lOpFIvFEgqFhTg4BEHRaJTBYJy5edX29vbnz5/xeLTZ2VkCgdDS0oKiqFarbWhouHPnzuPHj8+ZagQAXwuHwxQKZ X19vRAVQWAYlsvlAoEg70fGRSIROp2OV+zC61We5l2ZTMZqtep 0uk+fPhGJxLdv31oslvHx8Rs3bpSWlvJ4vL29PZVKxeFwqqqqW ltbwaIokE94sD+dTj8ug5Xfg1ssFplMVoh6JHhNvpmZmXg8nsv l/H5/NBqFYTiTyaTT6WAwiJey/Oq/klwux+Pxurq66urq2tvbHz16RCQS/rrr/X1dYvFUllZeePGDXxkczqdc3Nzf/3118LCQt5PHvijmUwmgUAQjUYLcfDd3d3l5eW8l47EMMxoNM7M zOClYOPxuM1mCwaDLpcrGAwGg0EGg6HT6dIzESsAABIlSURBVF wul9vt9vv9ZrM5FotB/5ucvrKyolKpvF6vy+WqrKwsLy/Hl1UZDEZNTc36+joEQTAMBwKB9vb2hYUFkJgH5JPNZltdXT1DP ZLT8Pv9HA5nd3c3j8dMJBJcLvfz58/HOwQIgsAwnM1mI5EIDMOxWGxzc1OlUonF4r29PbFYPD8/j0d79vT0DAwMnBzS3717RyAQmpqaMpkMgiBOpxO/OD0ez9DQUFNTU35PHgAgl8tFp9OtVmshDp5IJMRicR43rCORyP j4eHNzM5fL/bfiKzAMwzDs9XoNBoPf75dIJCqVCh+pnjx58ujRI5/Ph7/SZrPdvn27rKzszp07fr/5EHC4TCPx7NYLPk6cwD4H0dHRwwGw2AwFCIqP51OS6VSjUaTl6 OlUqnV1dWBgQGz2fzDs8UwDIZhPJPoOJZtcnKyuLi4v78fH+im pqZqampkMplOp/tqKxxMJoFCgWGYSqUKhcJCLFqiKCqRSObm5s6fxeNwOCYmJiYm Jo7HqDOIxWK1tbXl5eVtbW1SqbSzs5NMJp/zxADgp7FYrOnpafweJr9CodDTp08rKyuZTKbf74/H45FI5AyroxqN5sOHDwMDA/v7++c8JY/H09fXV1tb29HRIRKJQHVn4BfY3t6emJiw2Wz5PWw0GqVSqQ8fP qyurqZSqV6vd29vD5/Feb3eWCx2ysnb3t7e2NgYnU7PV5QMhmE2m81ms4GoLuDX8Hq9V Cr1zGEc/4THNA8PDw8NDQkEgkePHrW2tuZyuVgstru7a7fbhUIhl8vFF/HD4fC/3ZjFYjGhUNjW1sblcsHlAfw+gsEgk8nM42q4VqttbW3t6+tzuV yBQODevXt3797Fxyg8TMTj8RgMBrfbbTAYWCwWvm8WiUROXlex WGx+fr65uZlGo+U3lw8AfjF8JVCtVuflaCaTaXJyksFg4AkKqV Sqrq6upKREKpWefBmKonij093dXbPZvLm5KZPJrFar2+1Op9PJ ZFIsFk9OTmq12p9trQoAFx0MwxQKZXV1NRAInCejNBaLcTic1t ZWNpt9XNc1l8s1NjYSCIQPHz588114pgxe/tlut0skErFYzOfz+/r6QFQx8HtSqVSjo6Nra2tCoVCpVBqNRofD8bMpm9lslkKhvH/XiKRnFyTRBCkubn5ypUrDx48+P78EEXRXC4XCoV2dnZUKpXBYA DtF4Hf0O7uLo1Gs1qtmUxmb29vd3eXz+fPz88rlUqr1Xp4eJhM Jn+47xyPx+Vy+eTkpM1m+2odEsOw3t7eoqKisrIyk8l0mlPCMA xFUVAwD/jdpNPpzc3N8fFxtVp98jpJJpM2m02pVDIYDCaTqVar8V6K/7amb7fbR0dHv9M4bn5+nkAgFBUV9ff3g6gO4A+FV+Campra3t7 +5vwNRVG3272zs7O3tycSifDOclar1el0ZrPZ4yHo8PDw8+fP/f393wlHlMlkxcXFV65cuX/foEy0AHgQguHw2w2e2Fh4ZQ9OqLR6M7OjtVqlclkGxsbOp1Or9 cnEgm32z0zM7O6uvr9mzSDwVBWVnblypWSkhI83QYA/hT4JjWJRPr8+fPPZg+gKBoKhY6OjnZ2dng8nsFgGBkZGR0d/WEA18HBwc2bN69cuVJUVNTW1gaaVAF/Cvx6+/Lly/j4+N7e3nnWJxKJxO7u7ujo6GlWRCKRyJs3b65evXr9+nUWiwXW RYA/QjabVavVJBKJx+PlpZxrLBbDg7Z++EoMw7a3t3t7e1taWgpUZw UA8g9FUbxBKe6nfrh4d6j29vbV1dV8BXMgCMLn87Va7Q/PxO/3U6nUvr6+169fT05OgkYCwCWAYRheU2B7e1ulUul0OrPZ7PV6H Q6H1+sNBoPpdBoPU8xkMsd9g/EpHAzDMpns8+fPcrk8vzWJ8dWU7wccwzA8Pz/5s0buVyOb7IjCHL6glwA8GvgYZBsNttgMEilUrVavbGxIZPJuF yuVqs1m81Wq3VjY4PL5e7s7Ozv7x8eHuIb2bFYjMFgkEikQhSr 1Ol0YrH4+8Omx+N5/vz5p0+fjh+x2+1sNrsQDY0BIG98Ph+LxQoEAgiCpNPpbDabSCQ ODw/dbvfR0VE0GvX5fGazWavV2u12h8Oh0+kUCoXFYtnY2Hj16pVMJ ivEWZlMph/27PZ6vffv33/48OHxfHJ8fLy6unp7e7sQpwQAeZBKpYRCIV7s7TvwICkEQVAUx SeZyWRSoVCQSKQC9eJwu91sNvtkoR4URf1+/8kRDIbh3t7ekpKSjx8/JhIJFEUbGxvv378PRjng4jo8PCSTyWdrje10OhkMxpkL938fPm s9mU6eSCT6+voePnx4ch6bTCZfvXp18+bNN2/ekEikt2/fgpRT4OJCEGRjY0OpVJ4tOtHtds/Pz+/t7eX9xCAIQhCEwWBotVoURfHis9lsdnx8/OrVq62trRAEoShqNBrFYvHm5ubc3Fxzc3NPT49cLgcpcMDFFQ6 H8bu4s709FArNzs5yudz8ntUxfEUnFot9+PCBRCJBELSzs3P9+ nUikWgwGNLp9IcPH+7evdve3o6XGwoGg2B8Ay4uFEXX19dlMtm Zt49zudz6+vry8nKBFuW5XO7GxkY0Gv3777/xEEqpVNrQ0FBaWnrnzh2pVCqXy7u7u0tLS9vb28HGAHDR+f3+2 dnZ89QMxjDMYDAsLy8XomYeBEFbW1tkMjkaja6trZWWlpaWlnK 5XI/HMzY2RiQS6+rqIAjy+XzPnz+vrKxcXl4GyTvAhaZUKplM5jlrL eL7YGdbfTnNwefm5oLBIIIgAwMDBAKhq6sLgqBAINDc3NzW1oY HPe/u7j558qSnpwcUDgIurlAotLKycv6y+B6PRyqVFihRLRaLMZlMP CnB5/Pdu3ePSCTi24CRSCQQCGAYFgqFhoeHX7x4IRAIQIAlcHGZzWaJ RHL+YcHpdC4tLRmNxryc1VcQBOFwOMdFlGUy2a1btwYHB0++Jh QK8fl8gUAA2iMCFxcep5+XRtvJZJLL5fJ4vPMf6pvYbLZOp8OX RjKZzM7OzlfbgHhHDpAmB1xoGo1mYWHhPC0vjuG5M4VLxxaJRC wWC8wYgUssGo3iadf5OuDe3p5QKCzE0kU6ne7q6uLz+WADALjE rFarVCrNYzNhl8sllUrzHmkZDof5fP55tg0B4NfDMIzH4y0tLe VxULLZbMvLy/nN33G5XPPz8xwOB0RvAZcbhmHr6+vT09NbW1tnaMX2TdlsVqFQ aLXavBwNRVGbzTY/P8/lcr+fuQMAl0Mymdza2urv7xeLxXnJ44ZheH19fWtr6/yHymazMpmss7PzZOMBALj08LFuYmKCx+Pl5aZOKpXOz8+ff1Da 2trq6en5Ye1KALiU9Hp9Z2cnj8c7T/Q9XvD81atX1dXVKysrgUAgFAqdoeYPiqJqtZpCoZjN5jOfDABc aDAMq1Sq+fl5gUCQSqV+9u0+n4/H4/H5fCqV+vz58zt37kxPT7tcLrFYrNfrDw8Pd3Z2ThnAiaKoSCR6 9+6dXC7/+e8BAJfK/v4+Xp/r9FlzCILo9fpPnz719PRsbW05HA673f7ixYuWlhYURfHuAkajc WVlZX19Xa/X4527/21vDb/yh4eHVSpV/r4WAFxgu7u7LBaLQqGcLDTyTYFAwOVycTic9+/fz8zMHJcYCYVCVVVVlZWVx4GOqVTK7/erVKrl5WWTyWQwGPb29hKJxFebbIlEYnFxsaur6/wB1gBwmfj9fhaLNT8/29NvREEMRgMg4ODdDp9enpaJBKdvAMMhUK3bt0iEolfxTfncjm 8QJBIJNrc3DSbzUql8vDwEE9sy2QyIpHow4cPAoEAZHMDf5xYL EalUqenp/+Z/BYKhdhs9sePH0dGRkwm0z9TdZLJZG1tLYFAIJPJ3zx4JBKJx+O Hh4disVipVOr1eq1WS6VSx8bGTCYTSC0F/lBHR0cCgYBKpR6HkoTDYZPJRCKRPnz4wGazj46OvvnGXC7X0NC AN3n7ToY4hmGJROLo6Eir1a6srExOTqrV6oJ8EwC4LCKRyOrq6 tLS0s7OjkwmI5FIKysr8/PzOp3uO3vTCIK8fv0ab/J2moDpbDYbCoXC4TCInwT+aHgHUzybrq6u7tmzZ3w+PxwO/3BjGkXRtra2oqKioqKi1tbW/DYnAIDfBz7Tg2EY71qqVCodDgcEQdFo9PHjx0NDQ6df1ZidnS0 uLiYQCLW1tXnJxAOASymZTG5vb5vN5uNpIT6Xw/+Mx+N0Oh1fzFAqlWq12ul04i97/vx5f3/6RPVQqHQxsbG8vKyWCwG4cjAH8rj8YyPjz98+PD58+d4/QK89+LOzo5GozGbzeFwmEql6vX6g4MDn8+Xy+WOr7Hbt2/funXr9MX9M5mMVqslk8k/7N0BAL+nw8PD7u7u7u7uhYWF5eVlPIUUwzAqlbqyskKj0WZmZh KJRCwW++atV0NDQ3Fx8SkjsOLx+NLS0tu3b588edLW1gYmlsCf aHFx8e+/z6u1YMgSCAQiMViSqUSL8Swvb39ndBKvG7k6OjoaT6Lx+O9ePF CIpH4/X6XywXDMCidAPxxSCRSdXX15uYm/tdAINDY2Egmk4PBoNVq/WG2dX9/f1FR0dOnT3+YFpDNZjs7Ox8/fnycB+T1ehcXF00m0/m/BQBcUP8cVcRicXl5+YsXL/A7K6PRePPmzd7e3lMuQk5MTBQVFZWVleGVW78DRdGhoaFbt24d X95isfjmzZuzs7M/z0A4DKAYVij0cjl8pMXXjqdbm1tLSsra25uNhgMw8PD9fX1/xZC+U9TU1NFRUUEAmFjY+OrpwKBgNFoPLlZp1arq6qqamtrDw4 OksnkzMxMTU1NgbqrAsCvF4vF3r17V1lZqdfrof8tHyKRSNbW1 gYHBx89evTs2bOenp6fKk+Cj3JFRUWfP38+OTCiKMrj8aqqqo7 LxSYSCZVKVVdXd/Xq1fr6+uHh4cbGxpWVlTPk4AHAhZbL5fb29vB4SBaLRSQSa2tr c7lcJBLp7Ox88ODB69ev7XZ7MBhUKBQ/2+uUxWJdvXqVQCDU19fjYZN+vx+/WzMYDNevX6+qqsIT4ahUan19/d27d2tra2dnZwcHB3k8HqjMBfyGQqEQPoJls9nd3d3KykoCgUC j0cLhMJvNnpqaqq6ubm1tPVsnKpfLNTExMTU1dRxd2d/fj38WgiBv374tKirq6emBYZjBYIyMjNy5c+fu3bterxesVQK/rUQi8eLFCyKR2NHRwefzZ2dnb926VV5ejm+mJZPJqamp27dvDw wM/GxHKwzDDg4OlErlwcHBceTx6OgogUDo7+9XqVSfP3+urq4uLS2 l0WgIgmQymbm5uaqqqq6urjwWpQWAC8dms1VVVREIBBaLBUGQU CgsKSmpr6/Hn3W5XPX19S0tLT/blUan0w0MDPT09Dx69Oj58+d4N/BoNIonxb17987j8ezs7JSXl9+4cQPP6MnlcpOTk7W1tdvb2/n+lgBwkQiFQiKR+OjRo1gshiDIwsLC/Pw8BEGRSGRqaqqpqelna4z7fL6Ojo7+/n6LxTIxMVFSUvLgwQM8eMVut5eVlVVWVuIBKzQa7fXr1263O5f LbWxstLS0DA8Pg6ZTwG8um82+efOGQCAc74PhC4yhUEggEGxsb Jxy5TCbzVoslnA4bDabGxsbj4v/DA8PX716lU6n4zdpMzMzRCIR72aKomgikUBRFC+psLCwUKB2qg BwsVit1levXjEYjJMPYhj2U4NbOBx+/vx5fX39wsLC3bt3RSLR8eO3bt3q6OjAR7ZIJPLq1aumpqav3p7 JZED9EuAPEo/Hz9b1G4bheDyOomgulyORSGVlZSUlJQQC4fbt2/gtHAzDT58+nZubO76igsHgcY4PAAA/x263v3z5Ep+U4oW6ampqCAQCkUh8/PgxjUbr7e19/59fhvrAMCfy+v1VldXl5eXM5lMNpvd29tbWlpaWlra19fX29vb 3t7e3d2NB7UAAJAHKIpKJJJr166VlJRQqdR4PE4mk4lEYnd3dz gc9ng8wWAQ7G4DQD6hKNrT00MkEoeGhiAIikQib968mZycBOUl AaBQvF7v3bt3S0tL19bWIAiKRqMgiAQACovL5d6+ffurnQYAAA olnU47nU4wuAEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAcNL/A7dvYhPBz0ceAAAAAElFTkSuQmCC
http://www.ironmagazineforums.com/attachments/anabolic-steroid-profiles/34324d1313251122-super-dmz-rx-dimethazine-updated-2011-methyldrostanolone_superdrol.gif

Referrences

1. Biological activity of dimethazine in the protein-anabolic field.
2. Protracted action of protein anabolism in gynecological oncology and its effect on hepatic function.
3. A new steroid with protein anabolic activity: dimethazine.
4. Biological determination of the secondary hormonal activities of dimethazine.
5. Antigonadotropic action of a new steroid with anabolizing activity studied in the anterior pituitary gland of the castrated rat
6. Methasteron-Associated Cholestatic Liver Injury: Clinicopathologic Findings in 5 Cases”
7. Anabolic and androgenic activities of Bulbine natalensis stem in male Wistar rats
8. Effect of aqueous extract of Bulbine natalensis (Baker) stem on the sexual behaviour of male rats.

heavyiron
12-24-2010, 05:07 PM
I found an old i-force article on the web with some interesting claims about Dymethazine.

About Dymethazine:

In only 4 years since the Pro-Hormone ban of 2005 countless products have claimed to be as strong as or even stronger than the over the counter hormones once sold. After considerable time, energy, and research performed by i-Force's product formulation team, we are proud to announce the hormonal product everyone has been waiting for.


Featuring unheard of anabolic and myotropic effects, Dymethazine was compared to Methyltestosterone, Oxymethalone, Androstanazole and Testosterone Propionate in their protein-anabolic activity. Dymethazine was shown to have the HIGHEST myotropic (muscle building) effects out of any of the previously named steroids (Methyl-Test, Anadrol, Winstrol, and Testosterone Propionate)! In addition to this, it also displayed an ability to induce a higher rate of Nitrogen retention than Methyl-Test.(1)


In another study performed on Dymethazine, patients were administered Dymethazine for 45+ days. Liver values did not change for 50% of patients, while the other 50% noticed only modest to moderate increases in liver values(2). So, Dymethazine can increase liver values, however nowhere near the current methyl monsters on the market today. This means Dymethazine can be run for 4-6 weeks without the need of expensive liver support supplements.


Hormonal products that give huge strength/weight gains are usually associated with watery or wet gains due to large amounts of aromatization resulting in high levels of estrogen in the body. Too much estrogen can cause severe bloating, fat gain, and even potential growth problems. Dymethazine features 0% ability to aromatize and expresses an extremely weak androgenic activity (3). This means Dymethazine will produce intense gain, has very little to no liver impact, and will cause absolutely no estrogen related side effects.


Move beyond the pro-hormones of yesterday, and step into the future of Designer Steroids with Dymethazine. Consume 1-3 capsules, evenly spaced throughout the day. Do not use Dymethazine for longer than 6 weeks. Immediately begin PCT dosing protocol upon finishing Dymethazine. Wait at least 90 days before running Dymethazine again.


Referrences


1. Biological activity of dimethazine in the protein-anabolic field. Matscher, R.; Lupo, C.; De, P. Ruggieri. Lab. Ric. Ormonoter. Richter, Milan, Bollettino - Societa Italiana di Biologia Sperimentale (1962), 38 988-90. CODEN: BSIBAC ISSN: 0037-8771. Journal language unavailable. CAN 58:34623 AN 1963:34623 CAPLUS
2. Protracted action of protein anabolism in gynecological oncology and its effect on hepatic function. Dambrosio, F.; Donatelli, G. Fontana. Univ. Milan, Cancro, Il (1963), 16(5), 553-604. Journal language unavailable. CAN 62:11656 AN 1965:11656 CAPLUS
3. A new steroid with protein anabolic activity: dimethazine. De Ruggieri, P.; Matscher, R.; Gandolfi, C.; Chiaramonti, D.; Lupo, C.; Pietra, E.; Cavalli, R. Ormonoterap. Richter, Milan, Archivio di Scienze Biologiche (Bologna) (1963), 47(1), 1-19. CODEN: ASBIAL ISSN: 0004-0169. Journal language unavailable. CAN 60:46973 AN 1964:46973 CAPLUS

heavyiron
12-24-2010, 05:09 PM
Comparisons with methyltest, winny, anadrol and test prop showed better mytropic effect (muscle building) on the castrates with Dimethazine. In other words, mg for mg Dimethazine outperformed the above listed steroids for building muscle.

Biological activity of dimethazine in the protein-anabolic field.

Matscher, R.; Lupo, C.; De, P. Ruggieri. Lab. Ric. Ormonoter. Richter, Milan, Bollettino - Societa Italiana di Biologia Sperimentale (1962), 38 988-90. CODEN: BSIBAC ISSN: 0037-8771. Journal language unavailable. CAN 58:34623 AN 1963:34623 CAPLUS

Abstract

Dimethazine (I), 2,17-dimethyl-5-androstan-17-ol-3,3'-azine, was compared to methyltestosterone, oxymethalone, androstanazole and testosterone propionate in its protein-anabolic activity. The tests were made on castrated rats with a single hypodermic injection of 250 , on young male and female rats with increasing daily oral doses from 100 to 1000 for 30 days, and on adult male rats with daily oral doses of 1000 for 25 days. It was shown that I did not interfere with the growth of young animals; that adult rats treated with I gained, on an av., 20 g. more in wt. than the controls; and that I had a greater myotropic effect on castrates than the other steroids, and induced a higher N retention than methyltestosterone in adult males.

heavyiron
12-24-2010, 05:09 PM
Here is an abstract where females took 20mg for 45+ days...and it appears that less than half had any liver issues.

Protracted action of protein anabolism in gynecological oncology and its effect on hepatic function.

Dambrosio, F.; Donatelli, G. Fontana. Univ. Milan, Cancro, Il (1963), 16(5), 553-604. Journal language unavailable. CAN 62:11656 AN 1965:11656 CAPLUS

Abstract

Twenty mg. of dimethazine, an anabolizing steroid, was administered daily for 45-95 days to 11 gynecological patients. More than 50% of the cases showed no change in the bilirubinemia, the others showed modest to moderate increases. The glutamic-oxalacetic and the glutamic-pyruvic transaminases of the serum increased greatly in 3 patients. The albumins concn. usually decreased in the course of the treatment, while the globulins concn. did not change.

heavyiron
12-24-2010, 05:10 PM
This seems to support published reports that Dimethazine possesses a lower androgenic rating which would mean less androgenic sides and more anabolic muscle building effects.

A new steroid with protein anabolic activity: dimethazine.

De Ruggieri, P.; Matscher, R.; Gandolfi, C.; Chiaramonti, D.; Lupo, C.; Pietra, E.; Cavalli, R. Ormonoterap. Richter, Milan, Archivio di Scienze Biologiche (Bologna) (1963), 47(1), 1-19. CODEN: ASBIAL ISSN: 0004-0169. Journal language unavailable. CAN 60:46973 AN 1964:46973 CAPLUS

Abstract

Dimethazine (I) was evaluated for the following biol. activities: androgenic, N retaining, P retaining, and Ca retaining. The increase in uptake of -aminoisobutyric acid-1-14C and the increase in body wt. were also investigated. Data obtained, tabulated, and compared to those obtained with methyltestosterone established that I is a protein anabolic steroid with weak androgenic activity.

heavyiron
12-24-2010, 05:11 PM
Little to no progestenic/estrogenic activity...

Biological determination of the secondary hormonal activities of dimethazine.

Lupo, C.; Matscher, R.; Ruggieri, P. De. Lab. Ric. Ormonoter. Richter, Milan., Bollettino - Societa Italiana di Biologia Sperimentale (1962), 38 990-4. CODEN: BSIBAC ISSN: 0037-8771. Journal language unavailable. CAN 58:34624 AN 1963:34624 CAPLUS

Abstract

Expts. with rats and rabbits showed that dimethazine, 2,17-dimethyl-5-androstan-17-ol-3,3'-azine has, in contrast to its protein-anabolic properties, practically no estrogenic, progestational, and corticoid activity. Similarly, it has no effect on liver glycogen, and no antiinflammatory action on the anaphylactoid edema.

heavyiron
12-24-2010, 05:12 PM
Antigonadotropic action of a new steroid with anabolizing activity studied in the anterior pituitary gland of the castrated rat

Author Beghelli, V.; Mavrulis, A. Organization Univ. Bologna, Italy Publication Source Biochimica Applicata (1962), 9(No. 4), 179-88 Identifier-CODEN BIALAY ISSN 0006-298

Abstract:

Seventy-five female rats were divided into 5 groups; 15 served as controls; 60 were castrated and among these, 15 were treated with 17.alpha.-ethyl-19-nortestosterone (I), 15 with 17.alpha.-methyl-17.beta.-hydroxyandrosta-1,4-dien-3-one (II), and 15 with 2.alpha.,(Dimethazine) (III). With each of these steroids, treatment began 48 hrs. after the operation, with 1 mg. of the drug suspended in 0.5 ml. of saline (1% Tween 80 as suspending agent) once daily for 20 days by gavage. The last 15 received the vehicle only, according to the same schedule. The rats were sacrificed 24 hrs. after the last dose, and their pituitary glands and uteri examined. The castrates which received the vehicle only showed very pronounced gonadotropic pituitary hyperfunction, such as formation of castration cells and an increase in basophilic cells. Animals treated with I showed no castration cells at all, and only a small increase in basophilic cells. Those given II had some castration cells, and only a moderate redn. of basophilic cells compared with the untreated rats. The effect of III on the pituitary was almost negligible. In uterotropic activity, measured as the ratio of uterus wt. to body wt., I was most effective; III was intermediate; II showed almost no activity.


Conclusion:

This study showed little to no impact on the HPTA. This means that you will likely not experience the “shutdown” effect that is common to anabolics. This may make it easier to keep your gains in size and strength when your cycle is over.

heavyiron
08-13-2011, 09:07 AM
Clin Gastroenterol Hepatol. (http://www.ncbi.nlm.nih.gov/pubmed/18187367#) 2008 Feb;6(2):255-8. Epub 2008 Jan 9.

Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.

Shah NL (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shah%20NL%22%5BAuthor%5D), Zacharias I (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zacharias%20I%22%5BAuthor%5D), Khettry U (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Khettry%20U%22%5BAuthor%5D), Afdhal N (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Afdhal%20N%22%5BAuthor%5D), Gordon FD (http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gordon%20FD%22%5BAuthor%5D).

Source
Department of Gastroenterology, Lahey Clinic Medical Center, Burlington, Massachusetts 01805, USA.

Abstract

BACKGROUND & AIMS:

Methasteron is a nutritional supplement used to increase weight or accelerate the build-up of muscle mass. The aim of this study was to describe 5 cases of hepatotoxicity in patients using methasteron seen at tertiary-care medical centers.

METHODS:
A case report design was used.

RESULTS:
Five previously healthy patients who used methasteron developed jaundice 2 weeks after discontinuation; they presented to a tertiary-care medical center 2 weeks later. Within another 2 to 3 weeks, bilirubin levels peaked. About 12 weeks after initial presentation, all cases resolved with no identifiable residual hepatic dysfunction.

CONCLUSIONS:
Methasteron use can result in severe hepatotoxicity. Liver failure can worsen after initial presentation, especially within 2 weeks. With close observation and supportive care, acute hepatic injury should resolve.

PMID:18187367 [PubMed - indexed for MEDLINE]